Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
| ▸ | LPL | P06858 | 5/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25984165 | 0.79 | LPL (0.36) | LPLLIPGP2RX7 | |
| SCHEMBL16740533 | 0.76 | SNCA (0.36) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL16097750 | 0.75 | ASIC3 (0.34) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL16740503 | 0.75 | MALT1 (0.36) | LPLLIPGP2RX7 | |
| SCHEMBL1458765 | 0.74 | HSP90AA1 (0.50) | AURKAHSP90AA1PRKACAADORA2ALPL | |
| SCHEMBL29731779 | 0.73 | LPL (0.47) | LPLLIPG | |
| SCHEMBL710355 | 0.73 | LPL (0.42) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL24150109 | 0.71 | LPL (0.33) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL30379844 | 0.71 | LPL (0.33) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL856951 | 0.71 | DHFR (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135564-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 동화약품주식회사 | 2023-07-20 | — | — | WO | disclosed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2022208382-A1 | NOVEL DIALKOXYNAPHTHO[2,3-C]FURAN-1(3H)-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE OR SARS-COV-2 INFECTION DISEASE, COMPRISING SAME | 동화약품주식회사 | 2022-10-06 | — | — | WO | disclosed |
| US-9487533-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2114950-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2646020-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2010105008-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2207781-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2114949-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114950-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2099447-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009042607-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | NUDT1 3614/4885HRH4 3180/4885AURKA 330/4885 |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | NUDT1 2566/4885HRH4 2507/4885AURKA 692/4885 |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | NUDT1 2286/4885HRH4 3178/4885AURKA 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.